| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2001;32:262.)
© 2001 American Heart Association, Inc.
Comments, Opinions, and Reviews |
Venous Thromboembolism After Acute Stroke
From the Elderly Care Department, St. Thomas’ Hospital, London, England.
Correspondence to Dr J. Kelly, SpR in Elderly Care/GIM, Elderly Care Dept, C/O Alexandra Ward, 9th Floor North Wing, St. Thomas’ Hospital, Lambeth Palace Rd, Lambeth, London SE1 7EH, UK.
 |
Abstract |
|---|
Top
Abstract
IntroductionBackground—Treatment for venous thromboembolism (VTE) is highly effective in preventing morbidity and mortality, yet pulmonary embolism (PE) accounts for up to 25% of early deaths after stroke. This is because the current diagnostic paradigm is reactive rather than proactive: the clinician responds to VTE when it becomes symptomatic, in the expectation that initiation of treatment will prevent progression to more serious manifestations. This approach is flawed, because sudden death from PE is frequently unheralded and nonfatal symptomatic pulmonary emboli are often unrecognized or misdiagnosed.
Summary of Comment—Morbidity and mortality from PE could be reduced either by more effective thromboprophylaxis or earlier diagnosis and treatment of established VTE. The fact that early use of short-term, low-dose, unfractionated heparin (UFH) is not associated with sustained, clinically meaningful benefit suggests that a fundamental change in the diagnostic approach to VTE is needed, one which requires a greater appreciation that clinically apparent events are merely the tip of the thromboembolism iceberg.
Conclusions—Research into a strategy of screening for subclinical VTE in these patients is needed, with a view to identifying a subgroup at risk of progression to symptomatic and life-threatening events, in whom outcome might be improved by anticoagulation.
Key Words: cerebral infarction • deep vein thrombosis
|
Introduction |
|---|
In this article, an overview of data is presented on the incidence and natural history of venous thromboembolism (VTE) after stroke. Strategies of thromboprophylaxis, the morbidity and mortality associated with established VTE, and the risks of anticoagulant use in acute ischemic stroke are also discussed. It is argued that a strategy of screening for subclinical deep vein thrombosis (DVT) is required, though a further trial of thromboprophylactic low-dose, low-molecular-weight heparin (LMWH) may still be justified.
|
Incidence of DVT After Stroke |
|---|
Studies with 125I fibrinogen screening in patients with acute hemiplegic stroke have shown an incidence of DVT of approximately 50% within 2 weeks in the absence of heparin prophylaxis; the majority of these affect the paralyzed leg and are asymptomatic.1 Approximately two thirds of these are below-knee DVTs,2 in contrast to unselected (nonstroke) patients presenting with symptomatic DVT, in whom the majority are proximal.3 DVTs develop as early as the second day, with the peak incidence between days 2 and 7.1 The risk of DVT correlates with the degree of paralysis4 and is greater in older patients5 as well as those who have atrial fibrillation.6 Predilection for the paralyzed leg is probably explained by a combination of loss of the calf muscle pump and repeated minor trauma.7
DVT is also present in a significant proportion of patients during the rehabilitation phase of stroke, the risk being greater in those who are more immobile8 : in a study of 150 patients admitted to a stroke rehabilitation unit at, on average, 9 weeks after stroke, bilateral venography revealed DVT in 33%.8
|
Clinical Significance of Asymptomatic Proximal DVT After Stroke |
|---|
The main clinical significance of asymptomatic proximal DVT is its potential to cause fatal pulmonary embolism (PE). Indeed, the majority of symptomatic PEs in unselected patients are unheralded and arise from previously subclinical DVT.9
In a study of unselected patients performed before anticoagulants were in routine use, untreated, clinically apparent DVT was associated with a mortality from PE of up to 37%.10 The risk of fatal PE associated with untreated subclinical DVT is lower, though it remains significant. Early studies in patients with hip fractures found the risk to be around 10%,11 12 but a more recent overview in postoperative patients has suggested that predominantly subclinical DVT diagnosed by 125I fibrinogen scanning is associated with a 5% risk of fatal PE.13 14 Although there are few data on the natural history of untreated subclinical DVT in stroke patients, in one study patients with proximal subclinical DVT had a 35% risk of clinical PE.15
Fatal pulmonary emboli usually arise from proximal DVT,16 which accounts for one third of all DVTs in surgical patients.17 If it is assumed that the 5% of postoperative patients with untreated subclinical DVT who die from PE have proximal DVT, then 15% of subclinical proximal DVTs result in fatal PE. Three percent of stroke patients succumb to PE within 3 months,18 a mortality confined to the half who develop DVT.1 Because one third of these DVTs are proximal2 and most are silent,1 the data suggest that the mortality associated with untreated proximal subclinical DVT after stroke is some 15%, which is similar to that in postoperative patients.
A secondary concern is the potential to cause the postthrombotic syndrome, characterized by persistent pain and swelling, with or without venous ulceration.19 The incidence of this disorder approaches 90% in patients with untreated symptomatic DVT.10 Although it is recognized that many patients who present with this syndrome have no history of clinical VTE (the entire process having been clinically silent),20 the incidence after untreated asymptomatic DVT is unknown. The long-term incidence in patients with symptomatic, treated proximal DVT is approximately 30%3 ; however, there are conflicting data as to whether it occurs in patients with adequately treated asymptomatic proximal DVT.21 22
|
Clinical Significance of Asymptomatic Below-Knee DVT After Stroke |
|---|
A major concern in patients who have untreated below-knee DVT is the 20% risk of proximal extension,23 a subgroup that cannot accurately be predicted on clinical grounds.24 Clinical PE can, however, occur even in the absence of propagation,16 25 and routine ventilation-perfusion (VQ) scanning demonstrates silent PE in up to one third of patients who have isolated below-knee DVT.26 27 Although pulmonary emboli arising from below-knee DVTs are more likely to be small and asymptomatic and therefore less likely to be life threatening than those associated with proximal DVT,28 29 the risk of fatal PE attributable to untreated, nonpropagating below-knee DVT has not yet been defined. Symptomatic, isolated, below-knee DVT may cause the postthrombotic syndrome,29 but it is unclear whether this entity is a sequela in asymptomatic cases.
|
Clinical Significance of Pelvic Vein Thromboses After Stroke |
|---|
Pelvic vein thromboses may account for a significant minority of pulmonary emboli in unselected (nonstroke) patients: in a series of 353 autopsies of patients in whom pulmonary emboli were found, the pelvic veins accounted for 11.5% and the inferior vena cava 5% of the identifiable sources of emboli.30 However, the incidence and clinical significance of isolated pelvic and inferior vena cava thromboses after stroke is unknown, because these have not been detected by 125I fibrinogen scanning,31 the main screening tool used in early studies investigating the incidence of DVT after stroke.1
|
Incidence of PE After Stroke |
|---|
The incidence of clinical PE reported in the absence of heparin prophylaxis has varied considerably, depending on the methodology of the studies. In the International Stroke Trial (IST), the incidence was 0.8% at 2 weeks.32 Similarly, in a retrospective study of 607 patients who had acute stroke, PE was reported in 1% during the period of hospitalization.33 However, prospective studies that focused specifically on venous thromboembolic complications reported incidences of clinically apparent PE of 10% to 13% (excluding pulmonary emboli identified at autopsy that were asymptomatic during life).15 34 These data strongly suggest underascertainment in studies reporting much lower incidences of PE.
The risk of PE also extends into the rehabilitation phase. In a retrospective study of 363 patients who did not receive heparin prophylaxis and entered a rehabilitation unit 4 weeks after stroke, 4% developed PE (confirmed by VQ scanning) on average 11 days after entering the unit.35
Only 1 small study has prospectively screened for PE by using VQ scintigraphy. Dickmann et al36 studied a group of 23 patients 10 days after hemorrhagic stroke and found evidence of PE in 39%, though the proportion with symptoms was not stated. Autopsy studies show that half of the patients who die in hospital after the first 48 hours poststroke have evidence of PE,15 37 which suggests that pulmonary emboli are often subclinical and/or unrecognized after stroke.
|
Morbidity and Mortality Due to PE After Acute Stroke |
|---|
Pulmonary emboli account for 13% to 25% of early deaths after stroke.38 39 40 Although they may occur as early as day 3,41 fatal emboli are unusual in the first week40 and are most frequent between the second and fourth weeks, when they are the most common cause of death.18 Those more severely disabled are most likely to be affected,42 but PE may also occur in ambulatory patients.18
The mortality attributed to untreated clinical PE in unselected (nonstroke) hospitalized patients is approximately 30%.43 However, PE in stroke patients may have a higher mortality than that in other clinical settings15 41 44 ; in one series of stroke patients, half of the clinical pulmonary emboli presented as sudden death.41 The morbidity associated with nonlethal pulmonary emboli should not be overlooked; this may manifest primarily as impaired cardiorespiratory reserve adversely affecting rehabilitation and potentially influencing functional outcome.45
|
Difficulties in Diagnosis of Symptomatic PE After Acute Stroke |
|---|
The signs and symptoms of PE are notoriously nonspecific,46 and both underdiagnosis and misdiagnosis are well documented, particularly in the elderly.47 48 A number of factors make diagnosis even more difficult in poststroke patients, a group in whom antemortem diagnosis is especially poor.39 Patients may not complain of symptoms because of dysphasia, cognitive impairment, or mental obtundation.49 In addition, pneumonia, the illness for which PE is most often mistaken,47 is also a common complication after stroke.18 This can lead to misdiagnosis, particularly as it may be underappreciated that up to two thirds of patients with PE develop fever.50 Indeed, pneumonia and PE can commonly occur together, but the possibility of coexistent PE in a patient with strong clinical evidence of pneumonia is rarely considered; in a postmortem series of unselected patients found to have PE, pneumonia coexisted in 40%, though PE had not been diagnosed antemortem in any of the patients who had pneumonia.51 Finally, elderly patients with stroke may not be extensively investigated, and subtle clinical signs of PE, such as an asymptomatic mild increase in respiratory rate, are easily overlooked.
Stroke patients with suspected PE will usually undergo VQ scanning as the imaging modality of first choice. The importance of integrating this information with an assessment of the clinical probability of PE, either derived subjectively or by using scoring systems, has been stressed.9 52
|
Subclinical VTE |
|---|
Clinically manifested disease represents the tip of the thromboembolism iceberg.53 Screening studies in both stroke and postoperative patients,1 13 17 together with the low incidence of symptomatic DVT in patients with PE,9 demonstrate that the majority of DVTs are asymptomatic. Screening patients with symptomatic proximal DVT without clinical evidence of PE reveals evidence of subclinical PE in up to half.54 Furthermore, VQ scanning in predominantly asymptomatic postoperative patients reveals pulmonary emboli in 12% to 18%.55 56 57 Clearly, only a small proportion of pulmonary emboli produce symptoms.
|
Treatment of Established VTE |
|---|
Treatment of symptomatic VTE is highly effective in reducing morbidity and mortality. In an overview of 25 studies, recurrent fatal PE during a 3-month period of full anticoagulation occurred in only 1.5% and 0.4% of patients presenting with PE and DVT, respectively.58 In a meta-analysis of 13 trials comparing unfractionated heparin (UFH) with LMWH in the initial treatment of VTE, LMWH was found to be at least as effective as UFH and was associated with a significantly lower mortality.59
Although the need for anticoagulation in patients with symptomatic PE or proximal DVT is clear, the treatment of patients with symptomatic below-knee DVT is debated. The current consensus is that these patients should be either fully anticoagulated or followed up with serial noninvasive testing for 14 days,60 an approach shown to be safe in the absence of proximal extension.61 62 63 Optimal management of subclinical DVT has not been studied, but sensible conclusions can be drawn from a knowledge of the natural history of untreated DVT and the risks associated with anticoagulation, as discussed below.
|
Risks Associated With Anticoagulation in Acute Stroke |
|---|
Analysis of data from the IST allows a comparison of the effect of medium-dose heparin (12 500 U of UFH twice daily), initiated within 48 hours of ischemic stroke and continued for 2 weeks, to no heparin on a number of end points. Although this dosing regime reduced the risk of PE and recurrent ischemic stroke, the reduction was more than offset by an increased risk of hemorrhagic stroke transformation and extracranial hemorrhage. Overall, there was an excess risk of death or recurrent stroke and major nonfatal extracranial bleeds of 0.5% and 1.5%, respectively, during the treatment period.32 White et al64 studied the risk of warfarin-related complications in 22 000 unselected patients diagnosed with DVT over a 3-month period. In the subgroup of 1312 patients with a history of stroke, the readmission rate due to bleeding was 1.7%. In a comparison cohort of patients hospitalized because of pneumonia or cellulitis without DVT, this figure was 0.7%, which suggests that the excess risk attributable to warfarin in the stroke subgroup was 1.0%. The excess risk of intracranial hemorrhage in this subgroup was not specifically studied, though it was 0.1% in the group as a whole.
The balance of risks might therefore favor initiation of anticoagulation in established VTE after stroke, where the risk of major morbidity or mortality associated with untreated DVT exceeds about 3%, the combined risk of death, recurrent stroke, and major bleeding associated with a few days’ treatment with heparin followed by 3 months of warfarin after acute ischemic stroke. This suggests that patients with subclinical proximal DVT would benefit from treatment. The balance of risks is less clear for nonpropagating, below-knee DVT, though this may be affected by factors such as inadequate cardiorespiratory reserve, because even a small PE can be fatal in such patients.65
Most clinicians would now initiate treatment with LMWH rather than UFH. Although LMWH is associated with a lower risk of hemorrhage in medical patients,66 data comparing LMWH and UFH in stroke patients are insufficient to draw conclusions about their relative safety in this context.67 In addition, most diagnoses of clinical VTE are made several days after stroke onset,40 41 by which time the risk of hemorrhagic stroke transformation, greatest in the first 4 days, is likely to be lower.68 This approach might be associated with a more favorable risk-to-benefit ratio.
|
Heparin Thromboprophylaxis After Stroke |
|---|
Prophylactic use of UFH in surgical patients reduces the incidence of DVT, PE, fatal PE, and total mortality,13 and LMWH is at least as effective.69 An overview of 10 trials of prophylactic UFH or LMWH in more than 1000 patients with ischemic stroke has shown an approximate 80% reduction in the incidence of DVT as detected by 125I fibrinogen scanning or venography, though the numbers were too small to draw firm conclusions about the effect on the incidence of PE and total mortality.70 In a recent Cochrane review71 of 13 trials of anticoagulants in acute stroke, fatal and nonfatal PE were found to be significantly reduced by 39%; however, it should be noted that these trials were heterogenous and included a mixture of low- and medium-dose anticoagulant regimes.
In the IST, treatment with low-dose heparin (5000 U of UFH
subcutaneously twice daily) significantly reduced the combined risk of
death and recurrent stroke at 14 days from 12% to 10.8%, an effect
attributable predominantly to a reduced risk of recurrent
ischemic stroke, as PE was not significantly reduced. Increases
in the incidence of intracranial hemorrhage and of fatal or
transfusion-requiring extracranial bleeds did not reach significance
with this regime and are illustrated in the
Table
.32
Nevertheless, no reduction in overall mortality or disability could be
demonstrated at 6 months, and routine use of heparin prophylaxis after
stroke has therefore not been recommended subsequent to this
trial.71 One reason that the
short-term benefit of low-dose UFH was not sustained may be that
treatment was given for only 2 weeks, because most fatal PEs occur
between the second and fourth weeks after
stroke.18 In addition, there
was no information given as to how DVTs and PEs were diagnosed, so that
underascertainment may have occurred. A further trial of low-dose
heparin (preferably LMWH) for an extended period and with a more
systematic reporting of VTE may therefore be
justified.
|
|
Other Strategies to Prevent VTE After Stroke |
|---|
Graded elastic compression stockings are frequently used after stroke and have been shown to reduce the risk of DVT in surgical patients by about two thirds, though there are insufficient data to reach a definite conclusion about their effect on PE. Data are also lacking on their effectiveness in the context of stroke, or in combination with prophylactic-dose heparin,72 and they may be less acceptable to patients than subcutaneous heparin.73
Intermittent pneumatic compression is effective in preventing DVT in general surgical and neurosurgical patients as well as in patients undergoing elective knee and hip replacement, in whom it probably has an effect comparable in magnitude to that of LMWH.73 However, there have been no large studies in medical patients.74
Aspirin reduces the risk of VTE in surgical patients by at least one third,75 76 though it does not reduce overall mortality.75 In the International Stroke Trial, the incidence of fatal and nonfatal PE at 2 weeks was 0.6% in those treated with aspirin compared with 0.8% in controls, an effect that did not reach significance.32
|
The Case for a More Anticipatory Approach to VTE Diagnosis After Stroke |
|---|
Many pulmonary emboli that occur after stroke present as sudden death,41 and the majority of these patients do not have clinical evidence of DVT, the precursor to PE, before death.9 Because the treatment for VTE is highly effective,58 the current expectant approach to its diagnosis, particularly in the absence of heparin prophylaxis, should be questioned. A strategy of screening for VTE in these patients therefore warrants evaluation.
|
Methods of Screening for DVT After Stroke |
|---|
The choice of screening tool for DVT is problematic, because it would have to be noninvasive, inexpensive, and highly sensitive. Doppler ultrasound is a powerful technique for detecting symptomatic proximal DVT.77 However, combined data from 11 studies in high-risk postoperative patients indicate that the sensitivity for the diagnosis of asymptomatic proximal DVT is only 62% and that for asymptomatic below-knee DVT 48%.78 Although thrombi missed with ultrasound screening tend to be smaller and nonocclusive,79 it has been suggested that the technique may be unsatisfactory as a screening tool since many DVTs will not be detected.77 78 79 80 The utility of the technique for the detection of asymptomatic DVT after acute stroke has not specifically been evaluated.
The 125I fibrinogen test is no longer used because of the risk of transmission of infection with injected fibrinogen31 and impedance plethysmography is not useful for the detection of calf vein thromboses or asymptomatic DVT.77 Contrast venography remains the gold standard for diagnosing lower limb DVT, but would not be suitable because it is invasive and associated with a small risk of complications.77
MRI is noninvasive and allows simultaneous imaging of the venous system in both lower limbs. In addition, pelvic vein and inferior vena cava thromboses are accurately identified, an important advantage over other techniques.81 MR venography compares favorably with contrast venography for the diagnosis of symptomatic proximal DVT82 but has not been evaluated for the diagnosis of asymptomatic DVT. More recently, MR direct thrombus imaging has shown excellent sensitivity and specificity for the diagnosis of symptomatic above- and below-knee DVT.83 This technique allows direct visualization of thrombi so that equally favorable results might be expected in asymptomatic patients. Although availability is currently limited, MR technology is likely to play an increasingly important role in DVT diagnosis in the future.
|
D-Dimers as a Screening Tool for DVT After Stroke |
|---|
D-dimers are a cross-linked fibrin breakdown product generated from the degradation of the fibrin matrix of fresh venous thromboemboli.84 For symptomatic DVT or PE in unselected patients, ELISA assays have been shown to have an average diagnostic sensitivity of 97% at a threshold of 500 ng/mL, though the specificity is only 35% to 45%.85 86
Harvey et al87 investigated the utility of a D-dimer assay as a screening test for subclinical DVT in 105 patients who were, on average, 25 days poststroke and found that a threshold of 1092 ng/mL had a sensitivity of 100% and specificity of 66% for diagnosing DVT as detected by Doppler ultrasound. Although this study suggests that D-dimers may have a useful screening role, allowing the identification of a subgroup of patients who should undergo targeted imaging, the results cannot be extrapolated to patients in the first few days after stroke, because acute nonlacunar ischemic stroke increases D-dimer levels.88 89 90 91 92 Decay to baseline occurs over the next 30 days, 88 89 90 91 92 so the normal range differs in the acute and rehabilitation settings.91 A D-dimer threshold useful in the rehabilitation phase may therefore not be discriminatory in the first few days after stroke, the period during which most DVTs develop.1 It should also be noted that although several commercial D-dimer assays are now available, results from studies with one manufacturer’s test cannot necessarily be extrapolated to another.93 Further studies are required to examine the utility of D-dimers as a screening test for DVT in acute stroke.
|
Conclusions |
|---|
The morbidity and mortality attributable to VTE after stroke is unlikely to change with a perpetuation of current practice. As one of the most eminently treatable of stroke complications, and in the absence of more effective prophylaxis, research is needed into the development of noninvasive strategies of screening for subclinical DVT in these patients. Examples of future studies might include the assessment of MR technology, investigation of Doppler ultrasound for the diagnosis of subclinical proximal DVT, and the evaluation of D-dimers as a possible discriminator of DVT status in acute stroke, potentially facilitating targeted imaging in a subgroup with a high risk of underlying DVT.
Although optimal treatment of subclinical DVT after stroke is currently unknown, extrapolation of current evidence would suggest that the benefits of anticoagulation outweigh the risks associated with untreated subclinical proximal DVT. However, the balance of risks might generally favor an expectant approach in patients with adequate cardiorespiratory reserve who have isolated below-knee DVT, with repeat imaging to identify the subgroup in whom proximal propagation occurs.
Received June 20, 2000; revision received August 15, 2000; accepted August 31, 2000.
|
References |
|---|
1. Brandstater ME, Roth EJ, Siebens HC. Venous thromboembolism in stroke: literature review and implications for clinical practice. Arch Phys Rehabil. 1992;73:S-379–S-391.
2. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Magnani HN, Hull RD, Gent M. Double-blind randomised trial of ORG 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet. 1987;1:523–526.>[Medline] [Order article via Infotrieve]
3.
Prandoni P, Lensing
AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistina P,
Bernardi E, Prins MH. The long-term clinical course of acute deep
venous thrombosis. Ann Intern
Med. 1996;125:1–7.
4.
Landi G, D’Angelo
A, Boccardi E, Candilise L, Mannucci PM, Morabito A, Oralio EN. Venous
thromboembolism in acute stroke. Arch
Neurol. 1992;49:279–283.
5. Mulley GP. Avoidable complications of stroke. J R Coll Physicians Lond. 1982;16:94–97.[Medline] [Order article via Infotrieve]
6.
Noel P, Gregoire F,
Capon A, Lehert P. Atrial fibrillation as a risk factor for deep vein
thrombosis and pulmonary emboli in stroke patients.
Stroke. 1991;22:760–762.
7. Cope C, Reyes TM, Skversky NJ. Phlebographic analysis of the incidence of thrombosis in hemiplegia. Radiology. 1973;109:581–584.[Medline] [Order article via Infotrieve]
8. Bromfield EB, Reding MJ. Relative risk of deep venous thrombosis or pulmonary embolism post-stroke based on ambulatory status. J Neurol Rehabil. 1988;2:51–57.
9.
The PIOPED
Investigators. Value of the ventilation/perfusion scan in acute
pulmonary embolism: results of the prospective investigation of
pulmonary embolism diagnosis (PIOPED).
JAMA. 1990;263:2753–2759.
10. Byrne JJ. Phlebitis: a study of 748 cases at the Boston City Hospital. New Engl J Med. 1955;253:579–586.
11. Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patients. Lancet. 1959;981–989.
12. Sevitt S, Gallagher N. Venous thrombosis and pulmonary embolism. Br J Surg. 1961;213:475–489.>
13. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. New Engl J Med. 1988;318:1162–1173.[Medline] [Order article via Infotrieve]
14. Stein PD. Pulmonary Embolism. Baltimore, Md: Williams & Wilkins; 1996:12–18.
15. Warlow C, Ogston D, Douglas AS. Deep vein thrombosis of the legs after strokes. BMJ. 1976;1:1178–1183.
16. Havig CO. Source of pulmonary emboli. Acta Chir Scand. 1977;478(suppl):42–47.
17. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Ann Surg.1988;208;227–240.
18. Viitanen M, Winblad B, Asplund K. Autopsy-verified causes of death after stroke. Acta Med Scand. 1987;222:401–408.[Medline] [Order article via Infotrieve]
19. Villalta S, Bagatella P, Piccioli A, Lensing AW, Prins MH, Prandoni P. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome. Haemostasis. 1994;24(suppl 1):158a. Abstract.
20. Browse NL, Burnand KG, Irvine AT, Wilson NM. Diseases of the Veins. 2nd ed. Baltimore, Md: Arnold; 1999:292.
21.
Ginsberg JS,
Turkstra F, Buller HR, MacKinnon B, Magier A, Hirsh J. Postthrombotic
syndrome after hip or knee arthroplasty: a cross-sectional study.
Arch Intern Med. 2000;160:669–772.>
22. Siragusa S, Serafini S, Beltrametti C, Barone M, Piovella F. The incidence of post-thrombotic syndrome after asymptomatic post-operative deep vein thrombosis: an inception cohort study. Blood. 1998;92(suppl):47a. Abstract.
23.
Philbrick JT,
Becker DM. Calf deep venous thrombosis: a wolf in sheep’s clothing.
Arch Intern Med. 1988;148:2131–2138.
24. Lohr JM, James KV, Deshmukh RM, Hasselfeld KA. Calf vein thrombi are not a benign finding. Am J Surg. 1995;170:86–90.[Medline] [Order article via Infotrieve]
25. Browse NL, Thomas ML. Source of non-lethal pulmonary emboli. Lancet. 1974;1:258–259.[Medline] [Order article via Infotrieve]
26. Moreno-Cabral R, Kistner RL, Nordyke RA. Importance of calf vein thrombophlebitis. Surgery. 1976;80:735–742.[Medline] [Order article via Infotrieve]
27. Doyle DJ, Turpie AG, Hirsh J. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med. 1987;107:441–445.
28. Salzman EW. Venous thrombosis made easy. New Engl J Med. 1986;314:847–848.[Medline] [Order article via Infotrieve]
29.
Hirsh J, Hoak J.
Management of deep vein thrombosis and pulmonary embolism: a
statement for healthcare professionals.
Circulation. 1996;93:2212–2245.
30.
Modan B, Sharon
E, Jelin N. Factors contributing to the incorrect diagnosis of
pulmonary embolic disease.
Chest. 1972;62:388–393.
31. Browse NL, Burnand KG, Irvine AT, Wilson NM. Diseases of the Veins. 2nd ed. Baltimore, Md: Arnold. 1999;307:76–78.
32. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997;349:1569–1581.[Medline] [Order article via Infotrieve]
33.
Davenport RJ,
Dennis MS, Wellwood I, Warlow CP. Complications after acute stroke.
Stroke. 1996;27:415–420.
34. Warlow C, Ogston D, Douglas AS. Venous thrombosis following strokes. Lancet. 1972;1305–1306.
35. Subbarao J, Smith J. Pulmonary embolism during stroke rehabilitation. Ill Med J. 1984;328–332.
36. Dickmann U, Voth E, Schicha H, Henze T, Prange H, Emrich D. Heparin therapy, deep vein thrombosis and pulmonary embolism after intracerebral haemorrhage. Klin Wochenschr. 1988;66:1182–1183.[Medline] [Order article via Infotrieve]
37.
McCarthy ST,
Turner J. Low dose subcutaneous heparin in the prevention of deep vein
thrombosis and pulmonary emboli following acute stroke.
Age Ageing. 1986;15:84–88.
38.
Barer DH.
Dysphagia in acute stroke. BMJ. 1987;295:1137–1138. Letter.
39.
Bounds JV,
Wiebers DO, Whisnant JP, Okazaki H. Mechanisms and timing of deaths
from cerebral infarction.
Stroke. 1981;12:474–477.
40.
Brown M,
Glassenberg M. Mortality factors in patients with acute stroke.
JAMA. 1973;224:1493–1495.
41. Wijdicks EF, Scott JP. Pulmonary embolism associated with acute stroke. Mayo Clin Proc. 1997;72:297–300.[Abstract]
42.
Silver FL, Norris
JW, Lewis AJ, Hachinski VC. Early mortality following stroke: a
prospective review. Stroke. 1984;15:492–496.
43. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975;17:259–270.[Medline] [Order article via Infotrieve]
44.
Siddique RM,
Siddique MI, Connors AF, Rimm AA. Thirty-day case-fatality rates for
pulmonary embolism in the elderly.
Arch Intern Med. 1996;156:2343–2347.
45.
Johnston KC, Li
JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ, Faught RE Jr, Haley EC
Jr. Medical and neurological complications of ischemic stroke:
experience from the RANTTAS trial.
Stroke. 1998;29:447–453.
46.
Anonymous.
Prevention of venous thrombosis and pulmonary embolism.
JAMA. 1986;256:744–749.
47. Hampson NB. Pulmonary embolism: difficulties in the clinical diagnosis. Semin Respir Infect. 1995;10:123–130.[Medline] [Order article via Infotrieve]
48. Taubman LB, Silverstone FA. Autopsy proven pulmonary embolism among the institutionalized elderly. J Am Geriatr Soc. 1986;34:752–756.[Medline] [Order article via Infotrieve]
49. Chaudhuri GX, Costa JL. Clinical findings associated with pulmonary embolism in a rehabilitation setting. Arch Phys Med Rehabil. 1991;72:671–673.[Medline] [Order article via Infotrieve]
50. Murray HW, Ellis GC, Blumenthal DS, Sos TA. Fever and pulmonary thromboembolism. Am J Med. 1979;67:232–235.[Medline] [Order article via Infotrieve]
51. Goldhaber SZ, Hennekens CH, Evans DA. Factors associated with correct antemortem diagnosis of major pulmonary embolism. Am J Med. 1982;73:822–826.[Medline] [Order article via Infotrieve]
52. Bates SH, Ginsberg JS. Comparison of a clinical probability estimate and two clinical models in patients with suspected pulmonary embolism. Thromb Haemost. 2000;83:182–184.[Medline] [Order article via Infotrieve]
53.
Stein PD. Silent
pulmonary embolism. Arch Intern
Med. 2000;160:145–146.
54.
Meignan M, Rosso
J, Gauthier H, Brunengo F, Claudel S, Sagnard L, d’Azemar P, Simonneau
G, Charbonnier B. Systematic lung scans reveal a high frequency of
pulmonary embolism in patients with proximal deep venous
thrombosis. Arch Intern Med. 2000;160:159–164.
55. Browse NL, Clemenson G, Croft DN. Fibrinogen-detectable thrombosis in the legs and pulmonary embolism. BMJ. 1974;1:603–604.
56. Allgood RJ, Cook JH, Weedn RJ, Speed HK, Whitcomb WH, Greenfield LJ. Prospective analysis of pulmonary embolism in the postoperative patient. Surgery. 1970;68:116–122.[Medline] [Order article via Infotrieve]
57. Murphy ML, Dalrymple GV, Rivarola C. Silent pulmonary embolism in the elderly surgical patient. Geriatrics. 1972;27:87–93.
58.
Douketis JD,
Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal
pulmonary embolism in patients with treated venous
thromboembolism. JAMA. 1998;279:458–462.
59.
Dolovich LR,
Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis
comparing low-molecular-weight heparins with unfractionated heparin in
the treatment of venous thromboembolism.
Arch Intern Med. 2000;160:181–188.
60.
ACCP Consensus
Committee on Pulmonary Embolism. Opinions regarding the
diagnosis and management of venous thromboembolic disease.
Chest. 1996;109:233–237.
61. Huisman MV, Buller HR, ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. New Engl J Med. 1986;314:823–828.[Abstract]
62.
Huisman MV,
Buller HR, ten Cate JW. Utility of impedance plethysmography in the
diagnosis of recurrent deep vein thrombosis.
Arch Intern Med. 1988;148:681–683.
63. Hull RD, Raskob GE, Carter CJ. Serial impedance plethysmography in pregnant patients with clinically suspected deep vein thrombosis. Ann Intern Med. 1990;112:663–667.
64. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 1999;107:414–424.[Medline] [Order article via Infotrieve]
65.
Hull RD,
Raskob GE, Pineo GF, Brant RF. The low-probability lung scan: a need
for change in nomenclature. Arch Intern
Med. 1995;155:1845–1851.
66. Mismetti P, Laporte-Simitsidis S, Tardy B. Prevention of venous thromboembolism in Internal Medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 2000;83:14–19.[Medline] [Order article via Infotrieve]
67. Counsell C, Sandercock P. Low molecular weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. In: The Cochrane Database of Systematic Reviews; 1999.
68. Oppenheimer S, Hachinski V. Complications of acute stroke. Lancet. 1992;339:721–724.[Medline] [Order article via Infotrieve]
69. Nurmohamed NT, Rosendall FR, Buller HR, Dekker E, Hommes DW, Vandinbroucke JA, Briet E. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 1992;340:152–155.[Medline] [Order article via Infotrieve]
70.
Sandercock PA,
van den Belt AG, Lindley RI, Slattery J. Antithrombotic therapy in
acute ischaemic stroke: an overview of the completed randomised trials.
J Neurol Neurosurg
Psychiatry. 1993;56:17–25.
71. Gubitz G, Counsell C, Sandercock P, Signorini D. Anticoagulants for acute ischaemic stroke. In: The Cochrane Database of Systematic Reviews; 1999.
72.
Wells PS, Lensing
AW, Hirsh J. Graduated compression stockings in the preventiom of
post-operative venous thromboembolism.
Arch Intern Med. 1994;154:67–72.
73. Roth EJ. Prevention of thromboembolism in stroke rehabilitation patients. Top Stroke Rehabil. 1998;5:68–74.
74. Clagett PG, Anderson FA, Heit J. Prevention of venous thromboembolism. Chest. 1995;108(suppl): 312S–334S.>
75.
Antiplatelet
Trialists’ Collaboration. Collaborative overview of randomised trials
of antiplatelet therapy: reduction in venous thrombosis and
pulmonary embolism by antiplatelet prophylaxis among
surgical and medical patients.
BMJ. 1994;308:235–246.
76. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295–1302.[Medline] [Order article via Infotrieve]
77.
Anonymous. The
diagnostic approach to acute venous thromboembolism:
clinical practice guideline. Am J
Respir Crit Care Med. 1999;160:1043–1066.
78.
Wells PS, Lensing
AW, Davidson BL, Prins MH, Hirsh J. Accuracy of ultrasound for the
diagnosis of deep venous thrombosis in asymptomatic
patients after orthopedic surgery. Ann
Intern Med. 1995;122:47–53.
79.
Lensing AW, Doris
CI, McGrath FP, Cogo A, Sabine MJ, Ginsberg J, Prandoni P, Turpie AG,
Hirsh J. A comparison of compression ultrasound with color Doppler
ultrasound for the diagnosis of symptomless postoperative deep vein
thrombosis. Arch Intern Med. 1997;157:765–768.
80. Jongbloets LM, Lensing AW, Koopman MM, Buller HR, ten Cate JW. Limitations of compression ultrasound for the detection of symptomless postoperative deep vein thrombosis. Lancet. 1994;343:1142–1144.[Medline] [Order article via Infotrieve]
81.
Montgomery KD,
Potter HG, Helfet DL. Magnetic resonance venography to evaluate the
deep venous system of the pelvis in patients who have acetabular
fractures. J Bone Joint Surg
Am. 1995;77:1639–1649.
82. Polak JF, Fox LA. MR assessment of the extremity veins. Semin Ultrasound CT MRI. 1999; 20:36–46.
83. Fraser D, Moody A, Davidson I, Martel A, Morgan P. Diagnosis of lower limb deep venous thrombosis (DVT): prospective blinded analysis of magnetic resonance direct thrombus imaging. Vessel WMI Mechanics and Morphology; Society of Magnetic Resonance in Medicine; April 3–7, 2000; Denver, Colo. Abstract 364.
84. Kario K, Matsuo T, Kobayashi H. Which factors affect D-dimer levels in the elderly? Thromb Res. 1991;62:501–508.[Medline] [Order article via Infotrieve]
85.
Crippa L,
D’Angelo SV, Tomassini L, Rizzi B, D’ Alessandro G, D’Angelo A. The
utility and cost-effectiveness of
D-dimer measurements in the
diagnosis of deep vein thrombosis.
Haematologica. 1997;82:446–451.
86. Bounameaux H, de Moerloose P. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: an overview. Thromb Haemost. 1994;71:1–6.[Medline] [Order article via Infotrieve]
87.
Harvey RL, Roth
EJ, Yarnold PR, Durham JR, Green D. Deep vein thrombosis in stroke: the
use of plasma D-dimer level
as a screening test in the rehabilitation setting.
Stroke. 1996;27:1516–1520.
88.
Takano K,
Yamaguchi T, Kato H, Omae T. Activation of coagulation in acute
cardioembolic stroke. Stroke. 1991;22:12–16.
89.
Takano K,
Yamaguchi T, Uchida K. Markers of a hypercoagulable state following
acute ischemic stroke.
Stroke. 1992;23:194–198.
90. Giroud M, Dutrillaux F, Lemesle M, Volot F, Lorenzini JL, Becker F, Dumas R. Coagulation abnormalities in lacunar and cortical ischaemic stroke are quite different. Neurol Res.1998;20:15–18.
91.
Fisher M, Francis
R. Altered coagulation in cerebral ischaemia: platelet, thrombin
and plasmin activity. Arch
Neurol. 1990;47:1075–1079.
92. Feinberg WM, Bruck DC, Ring ME, Corrigan JJ. Hemostatic markers in acute stroke. Stroke.1989;20;592–597.
93.
Becker DM,
Philbrick JT, Bachhuber TL, Humphries JE.
D-dimer testing and acute
venous thromboembolism. Arch Intern
Med. 1996;156:939–946.
This article has been cited by other articles:
 |
|
 |
|
  C. S. Kase, G. W. Albers, C. Bladin, C. Fieschi, A. A. Gabbai, W. O'Riordan, G. F. Pineo, and on behalf of the PREVAIL Investigators Neurological Outcomes in Patients With Ischemic Stroke Receiving Enoxaparin or Heparin for Venous Thromboembolism Prophylaxis: Subanalysis of the Prevention of VTE After Acute Ischemic Stroke With LMWH (PREVAIL) Study Stroke, November 1, 2009; 40(11): 3532 - 3540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Shorr, W. L. Jackson, J. H. Sherner, and L. K. Moores Differences Between Low-Molecular-Weight and Unfractionated Heparin for Venous Thromboembolism Prevention Following Ischemic Stroke: A Metaanalysis Chest, January 1, 2008; 133(1): 149 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. van der Worp and J. van Gijn Acute Ischemic Stroke N. Engl. J. Med., August 9, 2007; 357(6): 572 - 579. [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Husemann, F. Muller, C. Krewer, S. Heller, and E. Koenig Effects of Locomotion Training With Assistance of a Robot-Driven Gait Orthosis in Hemiparetic Patients After Stroke: A Randomized Controlled Pilot Study Stroke, February 1, 2007; 38(2): 349 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-C. Diener, E. B. Ringelstein, R. von Kummer, H. Landgraf, K. Koppenhagen, J. Harenberg, I. Rektor, A. Csanyi, D. Schneider, J. Klingelhofer, et al. Prophylaxis of Thrombotic and Embolic Events in Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin: Results of the PROTECT Trial Stroke, January 1, 2006; 37(1): 139 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Lacut, L. Bressollette, G. Le Gal, E. Etienne, A. De Tinteniac, A. Renault, F. Rouhart, G. Besson, J. -F. Garcia, D. Mottier, et al. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage Neurology, September 27, 2005; 65(6): 865 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Leizorovicz and P. Mismetti Preventing Venous Thromboembolism in Medical Patients Circulation, December 14, 2004; 110(24_suppl_1): IV-13 - IV-19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr Effective Prophylaxis for Deep Vein Thrombosis After Stroke: Low-Dose Anticoagulation Rather Than Stockings Alone: For Stroke, December 1, 2004; 35(12): 2911 - 2912. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Dennis Effective Prophylaxis for Deep Vein Thrombosis After Stroke: Low-Dose Anticoagulation Rather Than Stockings Alone: Against Stroke, December 1, 2004; 35(12): 2912 - 2913. [Full Text] [PDF]
|
|
|
|
|
|
J. Kelly, A. Rudd, R.R. Lewis, C. Coshall, A. Moody, and B.J. Hunt Venous Thromboembolism After Acute Ischemic Stroke: A Prospective Study Using Magnetic Resonance Direct Thrombus Imaging Stroke, October 1, 2004; 35(10): 2320 - 2325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Cramer, G. Rordorf, J. H. Maki, L. A. Kramer, J. C. Grotta, W. S. Burgin, J. A. Hinchey, C. Benesch, K. L. Furie, H. L. Lutsep, et al. Increased Pelvic Vein Thrombi in Cryptogenic Stroke: Results of the Paradoxical Emboli From Large Veins in Ischemic Stroke (PELVIS) Study Stroke, January 1, 2004; 35(1): 46 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sandercock, M. Dennis, J. Kelly, A. Rudd, R. Lewis, and B.J. Hunt Venous Thromboembolism After Acute Stroke Response Stroke, June 1, 2001; 32 (6): 1443 - 1448. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||